Sign in
Enrolling by invitationPhase 2

Long-term safety of lunsekimig in adults with asthma

Tests lunsekimig under the skin in adults with asthma from earlier studies.

Key facts

Who runs it
Sanofi
Where
Benoni, Cape Town, Durban, and Pretoria, South AfricaSee the 6 sitesAlso in 23 other countries, 188 sites
Trial code
Registry title
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
Status
Enrolling by invitation
Phase
Phase 2
People taking part
900 people, planned
Started
30 Sept 2024
Expected to end
20 Jan 2031
Type of study
Interventional
Treatments tested
  • Lunsekimig
Record updated
17 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with asthma who finished the treatment period of study DRI16762 or ACT18301 and want to continue with lunsekimig.

Age
18 years or older
Sex
All sexes
Disease stage
Asthma, on stable moderate or high-dose inhaled steroid (ICS) treatment together with other controller medicines, as kept during the earlier study.
Earlier treatment
Must have completed the treatment period of study DRI16762 or ACT18301, including the end-of-treatment visit. Stable background asthma therapy is required.

Main reasons for not taking part

  • A new medical condition or treatment that, in the investigator's judgement, would affect taking part
  • A new lung disease that may reduce lung function
  • Current smoking or vaping of any products, or marijuana smoking
  • Allergy to lunsekimig or any of its ingredients
  • A side effect in the earlier study linked to lunsekimig that the investigator sees as an unreasonable risk

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol
  • Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:; For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone; For Study ACT18301: LABA with or without LTRA
  • Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures
  • Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:; For female participants:
  • incapable of becoming pregnant, or
  • not pregnant or breast feeding
  • no eggs donation or cryopreserving eggs; For male participants:; -- No sperm donation or cryopreserving sperm
  • Capable of giving signed informed consent

Who cannot take part

  • Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
  • Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • Participants who are receiving prohibited concomitant medications
  • Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant; The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
  • Participant who was diagnosed with a new pulmonary disease which may impair lung function
  • History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Participants are excluded from the study if any of the following criteria apply:
  • Current smoker or active vaping of any products and/or marijuana smoking

Where in South Africa

Also in 23 other countries, 188 sites

  • BenoniHospital not named in the registryEnrolling by invitation
  • BenoniHospital not named in the registryEnrolling by invitation
  • Cape TownHospital not named in the registryEnrolling by invitation
  • Cape TownHospital not named in the registryEnrolling by invitation
  • DurbanHospital not named in the registryEnrolling by invitation
  • PretoriaHospital not named in the registryEnrolling by invitation

About the trial

What the trial wants to find out

This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.

Read full original descriptionShow less

The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.

The group in the trial

  • LunsekimigTreatment being tested

    Participants will receive subcutaneous injection of lunsekimig according to established dosing interval

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Asthma Who Participated in Study DRI16762 or ACT18301
Plain-language title
Long-term safety of lunsekimig in adults with asthmaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 November 2026